On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.

The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0 million, up 44.3% year-over-year, significantly exceeding the consensus estimate of $314.2 million. Adjusted loss per share was $0.42, narrowing from $0.44 in the prior-year period, though slightly missing the $0.41 estimate.

Crucially, the company raised its full-year 2026 revenue guidance to $1.34 billion-$1.36 billion, up from the prior range of $1.30 billion-$1.32 billion, and well above the FactSet consensus of $1.31 billion. The strong top-line beat and raised outlook served as the primary catalysts for the overnight gain. Additionally, recent positive developments including FDA approval of Guardant360 Liquid CDx as a multi-cancer companion diagnostic, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and multiple analyst price target increases further supported bullish sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)